Pneumonia, an inflammatory condition of the lung usually due to bacterial and/or viral infection, is the third leading cause of death worldwide and a major cause of morbidity and mortality in children, adults and the elderly.

    FAIR will combine MultiOmics and computational biology to define the contribution of flagellin towards protection and the downstream immune effectors responsible for the gain of protection during combination therapy.

    FAIR will not only benefit from an existing pneumonia patient cohort (MARS), but will also establish a new cohort (BIO-PNEU), a first-in-man Phase I clinical trial (NEBUFLAG) and a socio-economic study on patients, volunteers and healthcare professionals (ADVIFLAG).

    Copyright © 2024 - FAIR - All Rights Reserved.